News & Articles

From concept to clinic, NExT gives researchers and developers access to Fujirebio’s unmatched expertise in neurological biomarker testing

The test operates using the company’s fully automated Lumipulse G1200 instrument system

Expected to be first commercially-available blood-based invitro diagnostic for patients being assessed for Alzheimer’s disease in the US

The partnership focuses on development, manufacturing and clinical adoption of neurodegenerative disease assays

The test is intended for the detection of promoter hypermethylation of the genes

The collaboration aims to impact the evolution and enhancement of immunoassay solutions in India

The new assay allows for the quantitative measurement of Tau phosphorylated

The collaboration aims to utilize high-quality reagent materials, develop new parameters, and advance technologies in the future

The partnership seeks to expand access to patient-friendly diagnostics

Fujirebio adds another two markers to its fully automated blood-based biomarker portfolio

The new biomarker tests will allow further study of the clinical utility of NfL in diverse disease conditions

Strategic partnership aims to accelerate biomarker development to improve the diagnosis of Alzheimer’s disease and and other neurological disorders

Plans to accelerate new platform development based on ultra-high sensitivity detection technology